RU2015138544A - Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран - Google Patents
Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран Download PDFInfo
- Publication number
- RU2015138544A RU2015138544A RU2015138544A RU2015138544A RU2015138544A RU 2015138544 A RU2015138544 A RU 2015138544A RU 2015138544 A RU2015138544 A RU 2015138544A RU 2015138544 A RU2015138544 A RU 2015138544A RU 2015138544 A RU2015138544 A RU 2015138544A
- Authority
- RU
- Russia
- Prior art keywords
- sequence
- polynucleotide
- composition
- ogt
- nucleotides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01186—Glycogenin glucosyltransferase (2.4.1.186)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01255—Protein O-GlcNAc transferase (2.4.1.255)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Power Engineering (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775937P | 2013-03-11 | 2013-03-11 | |
| US61/775,937 | 2013-03-11 | ||
| PCT/US2014/023525 WO2014164805A1 (en) | 2013-03-11 | 2014-03-11 | Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2015138544A true RU2015138544A (ru) | 2017-04-18 |
| RU2015138544A3 RU2015138544A3 (cg-RX-API-DMAC10.html) | 2018-01-17 |
Family
ID=51658978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015138544A RU2015138544A (ru) | 2013-03-11 | 2014-03-11 | Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран |
Country Status (13)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12146883B2 (en) * | 2018-12-06 | 2024-11-19 | Biocapital Holdings, Llc | Glucose sensors and methods of use thereof |
| CN111234022B (zh) * | 2019-12-16 | 2024-03-22 | 江苏省药物研究所有限公司 | 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 |
| CN112707955B (zh) * | 2020-12-21 | 2022-01-18 | 山东润德生物科技有限公司 | 提高N-乙酰氨基葡萄糖产量的RamAM转录因子突变体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL108367A0 (en) * | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| WO1998044123A2 (en) * | 1997-03-31 | 1998-10-08 | The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services | O-LINKED GlcNAc TRANSFERASE (OGT): CLONING, MOLECULAR EXPRESSION, AND METHODS OF USE |
| HK1042706A1 (zh) * | 1998-08-03 | 2002-08-23 | 东卡罗来纳大学 | 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理 |
| US7098190B1 (en) * | 1999-01-27 | 2006-08-29 | Coda Therapeutics Ltd. | Formulations comprising antisense nucleotides to connexins |
| US20090117599A1 (en) * | 2005-12-22 | 2009-05-07 | Jun Hirabayashi | METHOD OF DETECTING SUGAR CHAINS HAVING GlcNAc TRANSFERRED BY GnT-V |
| WO2010042228A2 (en) * | 2008-10-10 | 2010-04-15 | Cornell University | Methods for predicting disease outcome in patients with colon cancer |
| US20120046186A1 (en) * | 2010-08-20 | 2012-02-23 | Pelham Robert J | Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs |
| JP2012083193A (ja) * | 2010-10-12 | 2012-04-26 | Univ Of Tokyo | ヒストンタンパク質のグリコシル化を検出するための方法、並びに当該方法に用いられる抗体 |
-
2014
- 2014-03-11 US US14/774,800 patent/US20170166897A1/en not_active Abandoned
- 2014-03-11 BR BR112015022701A patent/BR112015022701A2/pt not_active IP Right Cessation
- 2014-03-11 JP JP2016501273A patent/JP2016513968A/ja not_active Withdrawn
- 2014-03-11 MX MX2015012124A patent/MX2015012124A/es unknown
- 2014-03-11 WO PCT/US2014/023525 patent/WO2014164805A1/en not_active Ceased
- 2014-03-11 AU AU2014248966A patent/AU2014248966A1/en not_active Abandoned
- 2014-03-11 KR KR1020157028279A patent/KR20150126048A/ko not_active Withdrawn
- 2014-03-11 SG SG11201507211YA patent/SG11201507211YA/en unknown
- 2014-03-11 CN CN201480026966.0A patent/CN105408480A/zh active Pending
- 2014-03-11 CA CA2905337A patent/CA2905337A1/en not_active Abandoned
- 2014-03-11 RU RU2015138544A patent/RU2015138544A/ru not_active Application Discontinuation
- 2014-03-11 EP EP14779180.0A patent/EP2970978A4/en not_active Withdrawn
-
2015
- 2015-09-11 CL CL2015002599A patent/CL2015002599A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016513968A (ja) | 2016-05-19 |
| CL2015002599A1 (es) | 2016-08-26 |
| WO2014164805A1 (en) | 2014-10-09 |
| MX2015012124A (es) | 2016-04-28 |
| CN105408480A (zh) | 2016-03-16 |
| US20170166897A1 (en) | 2017-06-15 |
| BR112015022701A2 (pt) | 2018-09-25 |
| SG11201507211YA (en) | 2015-10-29 |
| CA2905337A1 (en) | 2014-10-09 |
| EP2970978A1 (en) | 2016-01-20 |
| KR20150126048A (ko) | 2015-11-10 |
| EP2970978A4 (en) | 2016-11-02 |
| AU2014248966A1 (en) | 2015-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010532163A5 (cg-RX-API-DMAC10.html) | ||
| JP2016506240A5 (cg-RX-API-DMAC10.html) | ||
| TW201922264A (zh) | 用於抑制類血管生成素蛋白-3(ANGPTL3)表現的RNAi藥劑及組合物及使用方法 | |
| JP2011508605A5 (cg-RX-API-DMAC10.html) | ||
| JP2023505273A5 (cg-RX-API-DMAC10.html) | ||
| JP2011506447A5 (cg-RX-API-DMAC10.html) | ||
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| BR112015024764B1 (pt) | Oligonucleotídeos de tgf-beta modificados, seu uso e composições farmacêuticas que os compreendem | |
| JP2018533956A5 (cg-RX-API-DMAC10.html) | ||
| JP7829478B2 (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| EP3491129A1 (en) | Methods of treating osmidrosis | |
| Mansour et al. | miRNAs and their multifaceted role in cutaneous wound healing | |
| JP2016513968A5 (cg-RX-API-DMAC10.html) | ||
| RU2015112131A (ru) | КиРНК И ИХ ИСПОЛЬЗОВАНИЕ В СПОСОБАХ И КОМПОЗИЦИЯХ ДЛЯ ЛЕЧЕНИЯ И/ИЛИ ПРОФИЛАКТИКИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ | |
| CN116173218B (zh) | 蛋白转运抑制剂在制备用于治疗或缓解牙周炎的药物中的用途 | |
| WO2016069717A1 (en) | Inhibitors of mirnas in regulation of arterial stiffness and uses thereof | |
| WO2022206784A1 (zh) | 一种用于治疗肺纤维化的rna递送系统 | |
| CN102643811B (zh) | 人miR-1229的反义寡聚核苷酸及其应用 | |
| CN102140469A (zh) | 人miR-1233反义核酸及其应用 | |
| ES3000735T3 (en) | Treatment method of left ventricular dysfunction following an acute myocardial infarction | |
| CN102643806B (zh) | 人miR-1913的反义寡聚核苷酸及其应用 | |
| KR20250160411A (ko) | miR 145 억제제를 유효성분으로 포함하는 심근경색증의 치료용 조성물 | |
| CN121943948A (zh) | 一种靶向沉默肝脏Igf1r基因的GalNAc-Igf1r siRNA在制备治疗皮肤损伤的药物中的应用 | |
| HK40091624B (en) | Treatment method of left ventricular dysfunction following an acute myocardial infarction | |
| HK40091624A (en) | Treatment method of left ventricular dysfunction following an acute myocardial infarction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180504 |